JP2007511463A5 - - Google Patents

Download PDF

Info

Publication number
JP2007511463A5
JP2007511463A5 JP2006522051A JP2006522051A JP2007511463A5 JP 2007511463 A5 JP2007511463 A5 JP 2007511463A5 JP 2006522051 A JP2006522051 A JP 2006522051A JP 2006522051 A JP2006522051 A JP 2006522051A JP 2007511463 A5 JP2007511463 A5 JP 2007511463A5
Authority
JP
Japan
Prior art keywords
component
luminal surface
agent
vascular endothelium
transport agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006522051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511463A (ja
Filing date
Publication date
Priority claimed from US10/631,481 external-priority patent/US20040115128A1/en
Application filed filed Critical
Publication of JP2007511463A publication Critical patent/JP2007511463A/ja
Publication of JP2007511463A5 publication Critical patent/JP2007511463A5/ja
Pending legal-status Critical Current

Links

JP2006522051A 2003-07-31 2004-07-29 作用物質の組織特異的送達のための内皮の標的化 Pending JP2007511463A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/631,481 US20040115128A1 (en) 1995-09-08 2003-07-31 Targeting endothelium for tissue-specific delivery of agents
PCT/US2004/024448 WO2005012489A2 (en) 2003-07-31 2004-07-29 Targeting endothelium for tissue-specific delivery of agents

Publications (2)

Publication Number Publication Date
JP2007511463A JP2007511463A (ja) 2007-05-10
JP2007511463A5 true JP2007511463A5 (enExample) 2007-09-13

Family

ID=34115771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006522051A Pending JP2007511463A (ja) 2003-07-31 2004-07-29 作用物質の組織特異的送達のための内皮の標的化

Country Status (6)

Country Link
US (2) US20040115128A1 (enExample)
EP (1) EP1664272A4 (enExample)
JP (1) JP2007511463A (enExample)
AU (1) AU2004261988B2 (enExample)
CA (1) CA2537899A1 (enExample)
WO (1) WO2005012489A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139058B2 (ja) 2004-06-02 2013-02-06 シドニー キンメル キャンサー センター 新形成または新生脈管構造の検出、画像化および処置のための血管標的
WO2005117999A2 (en) * 2004-06-02 2005-12-15 Sidney Kimmel Cancer Center Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
US7810718B2 (en) * 2005-05-12 2010-10-12 Cubic Corporation Variable thickness data card body
US8273071B2 (en) 2006-01-18 2012-09-25 The Invention Science Fund I, Llc Remote controller for substance delivery system
US7699834B2 (en) 2005-11-09 2010-04-20 Searete Llc Method and system for control of osmotic pump device
US8992511B2 (en) * 2005-11-09 2015-03-31 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US8083710B2 (en) 2006-03-09 2011-12-27 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
US8617141B2 (en) * 2005-11-09 2013-12-31 The Invention Science Fund I, Llc Remote controlled in situ reaction device
US9067047B2 (en) * 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
US8936590B2 (en) * 2005-11-09 2015-01-20 The Invention Science Fund I, Llc Acoustically controlled reaction device
US20070106277A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Remote controller for substance delivery system
US20080140057A1 (en) 2006-03-09 2008-06-12 Searete Llc, A Limited Liability Corporation Of State Of The Delaware Injectable controlled release fluid delivery system
EP3019203A4 (en) 2013-07-09 2017-04-26 President and Fellows of Harvard College Endothelial cell genes and uses thereof
US10307487B2 (en) 2013-07-09 2019-06-04 President And Fellows Of Harvard College Microvessel endothelial cell surface markers and uses thereof
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602005A (en) * 1989-03-03 1997-02-11 The University Of Virginia Alumni Patents Foundation Primate intra-acrosomal sperm antigen for use in a contraceptive vaccine
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5281700A (en) * 1992-08-11 1994-01-25 The Regents Of The University Of California Method of recovering endothelial membrane from tissue and applications thereof
CA2228604A1 (en) * 1995-09-08 1997-03-13 Jan E. Schnitzer Isolation of microdomains of caveolae and gpi-anchored proteins
US5776770A (en) * 1995-09-08 1998-07-07 Beth Israel Deaconess Medical Center Isolation and uses of caveolae
US20030008819A1 (en) * 1995-09-08 2003-01-09 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents

Similar Documents

Publication Publication Date Title
Zhang et al. Engineered exosomes from different sources for cancer-targeted therapy
Sun et al. In vivo targeting and imaging of atherosclerosis using multifunctional virus-like particles of simian virus 40
Krumpe et al. The use of phage-displayed peptide libraries to develop tumor-targeting drugs
Tandle et al. Tumor vasculature‐targeted delivery of tumor necrosis factor‐α
Nishio et al. Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection
Brown Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications
Toh et al. Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma
Chang et al. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer
Winter et al. Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
Agemy et al. Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32
Asham et al. Management of hepatocellular carcinoma
JP2005523687A5 (enExample)
Ji et al. Targeted delivery of interferon‐α to hepatitis B virus‐infected cells using T‐cell receptor‐like antibodies
JP2009197002A5 (enExample)
ES2363044T3 (es) Péptidos específicos para las metástasis y sus aplicaciones en diagnóstico y terapéuticas.
JP2017507936A5 (enExample)
Ma et al. Anti-tumor effects of the peptide TMTP1-GG-D (KLAKLAK) 2 on highly metastatic cancers
Wu et al. Peptide‐mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy
JP2015513083A5 (enExample)
Jung et al. Characterization of hepatocellular carcinoma cell lines based on cell adhesion molecules
JP2008501701A5 (enExample)
US20180289844A1 (en) Methods and compositions for cancer diagnosis
Choi et al. Knockdown of HIF-1α and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells
JP2019537619A5 (enExample)
Costello et al. Perfusion of 99Tcm‐labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target